Cabometyx (cabozantinib) — Medica
Non-small cell lung cancer
Initial criteria
- age ≥ 18 years
- RET rearrangement positive tumor
- progressed on first-line therapy with pralsetinib or selpercatinib
Approval duration
1 year
Non-small cell lung cancer
1 year